Cited 0 times in
Omission of axillary lymph node dissection in patients with ypN plus breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.date.accessioned | 2024-05-30T07:11:30Z | - |
dc.date.available | 2024-05-30T07:11:30Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 0748-7983 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199627 | - |
dc.description.abstract | Background: We evaluated the impact of omitting axillary lymph node dissection (ALND) on oncological outcomes in breast cancer patients with residual nodal disease after neoadjuvant chemotherapy (NAC). Methods: The medical records of patients who underwent NAC followed by surgical resection and had residual nodal disease were retrospectively reviewed. In total, 1273 patients from 12 institutions were included; all underwent postoperative radiotherapy. Axillary surgery consisted of ALND in 1103 patients (86.6%) and sentinel lymph node biopsy (SLNBx) alone in 170 (13.4%). Univariate and multivariate an-alyses of disease-free survival (DFS) and overall survival (OS) were performed before and after propensity score matching (PSM). Results: The median follow-up was 75.3 months (range, 2.5-182.7). Axillary recurrence rates were 4.8% in the ALND group (n = 53) and 4.7% in the SLNBx group (n = 8). Before PSM, univariate analysis indicated that the 5-year OS rate was inferior in the ALND group compared to the SLNBx group (86.6% vs. 93.3%, respectively; P = 0.002); multivariate analysis did not show a difference between groups (P = 0.325). After PSM, 258 and 136 patients were included in the ALND and SLNBx groups, respectively. There were no significant differences between the ALND and SLNBx groups in DFS (5-year rate, 75.8% vs. 76.9%, respectively; P = 0.406) or OS (5-year rate, 88.7% vs. 93.1%, respectively; P = 0.083). Conclusions: SLNBx alone did not compromise oncological outcomes in patients with residual nodal disease after NAC. The omission of ALND might be a possible option for axillary management in patients treated with NAC and postoperative radiotherapy.(c) 2022 Elsevier Ltd, BASO -The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | EJSO | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Axilla / pathology | - |
dc.subject.MESH | Breast Neoplasms* / surgery | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Node Excision / adverse effects | - |
dc.subject.MESH | Lymph Nodes / pathology | - |
dc.subject.MESH | Lymphatic Metastasis / pathology | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Neoplasm, Residual / pathology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sentinel Lymph Node Biopsy | - |
dc.subject.MESH | Sentinel Lymph Node* / pathology | - |
dc.title | Omission of axillary lymph node dissection in patients with ypN plus breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Younghee Park | - |
dc.contributor.googleauthor | Young Seob Shin | - |
dc.contributor.googleauthor | Kyubo Kim | - |
dc.contributor.googleauthor | Kyung Hwan Shin | - |
dc.contributor.googleauthor | Ji Hyun Chang | - |
dc.contributor.googleauthor | Su Ssan Kim | - |
dc.contributor.googleauthor | Jin Hong Jung | - |
dc.contributor.googleauthor | Won Park | - |
dc.contributor.googleauthor | Haeyoung Kim | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.contributor.googleauthor | Sung Ja Ahn | - |
dc.contributor.googleauthor | Myungsoo Kim | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Hye Jung Cha | - |
dc.contributor.googleauthor | Tae Gyu Kim | - |
dc.contributor.googleauthor | Hae Jin Park | - |
dc.contributor.googleauthor | Sun Young Lee | - |
dc.identifier.doi | 10.1016/j.ejso.2022.11.099 | - |
dc.contributor.localId | A00744 | - |
dc.relation.journalcode | J00847 | - |
dc.identifier.eissn | 1532-2157 | - |
dc.identifier.pmid | 36470801 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0748798322008277 | - |
dc.subject.keyword | Axillary lymph node dissection | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Neoadjuvant chemotherapy | - |
dc.subject.keyword | Residual nodal disease | - |
dc.subject.keyword | Sentinel lymph node biopsy | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 589 | - |
dc.citation.endPage | 596 | - |
dc.identifier.bibliographicCitation | EJSO, Vol.49(3) : 589-596, 2023-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.